$87.02
-0.82%Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Mรฉniรจre's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
ABT โข NYSE
| Abbott Laboratories Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
6.5B | 13.4B | 5.7B | 6.9B | 7.1B | 4.5B | 3.7B | 2.4B | 477M | 1.4B | 1.6B | 2.3B | 2.6B | 6B | 4.7B | 4.6B | 5.7B | 4.7B | 3.6B | 1.7B | |
3.1B | 3.2B | 3.2B | 3.3B | 3.5B | 3.3B | 3B | 3.3B | 3B | 1.4B | 1.5B | 1.5B | 1.7B | 2.8B | 3B | 2.6B | 2.1B | 1.8B | 1.9B | 1.6B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 293M | -1.2B | 248M | 314M | 429M | 395M | 1,850.5B | 968.8B | 328.4B | 508.7B | 1B | -4.8M | -44.5M | |
664M | 673M | 644M | 685M | 640M | 546M | 519M | 477M | 406M | 310M | 292M | 246M | 262M | 433M | 383M | 387.2M | 366.4M | 347M | 46.3M | 136.5M | |
65M | 482M | 126M | 215M | 55M | 425M | 247M | 32M | 912M | 1.4B | -539M | -342M | -391M | -1,848.5B | -967.9B | -328B | -509.3B | -545M | 744.5M | 2.5B | |
(0.0) | (1.7B) | (1.5B) | (1.9B) | (1.9B) | (970M) | (930M) | (740M) | (570M) | (620M) | (631M) | (448M) | (1B) | (1.4B) | (1.8B) | (809.7M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-803M | -9.2B | -2.5B | -1.5B | -771M | -892M | -1.3B | -148M | 1.9B | -1.5B | -156M | -490M | -1.2B | -1.9B | 1.1M | 658.8M | -341.4M | -39.7M | -1.1B | -548.1M | |
9.6B | 8.6B | 7.3B | 9.6B | 10.5B | 7.9B | 6.1B | 6.3B | 5.6B | 3.2B | 3B | 3.7B | 3.3B | 9.3B | 9B | 8.7B | 7.3B | 7.3B | 5.2B | 5.3B | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-2.2B | -2.2B | -2.2B | -1.8B | -1.9B | -2.2B | -1.6B | -1.4B | -1.1B | -1.1B | -1.1B | -1.1B | -1.1B | -1.8B | -1.5B | -1B | -1.1B | -1.3B | -1.7B | -1.3B | |
-105M | (1M) | -837M | (48M) | -53M | (16M) | -122M | (48M) | -8.4B | -55M | (2.3B) | -3.3B | -580M | -1.2B | -672.5M | -9.4B | -2.4B | -250M | (0.0) | -7.9B | |
-167M | -169M | -159M | -185M | -173M | -83M | -103M | -131M | -210M | -2.8B | -4.9B | -1.5B | -10.1B | -12B | -5.1B | -805.9M | -249M | -923.9M | (535.6M) | -2.1B | |
3M | 28M | 43M | 152M | 77M | 10M | 21M | 73M | 129M | 3.7B | 4.1B | 5.6B | 7.8B | 8.9B | 5.6B | 954.4M | 16.3M | 449.2M | 17.8M | 18.5M | |
18M | 9M | 22M | 22M | 26M | 19M | 27M | 48M | 35M | 42M | 52M | 75M | 21M | 2.7M | 1.9B | -1.9B | -6.4M | -75.1M | -33.5M | -25.7M | |
-2.4B | -2.3B | -3.1B | -1.7B | -2B | -2.2B | -1.8B | -1.4B | -9.6B | -248M | (406M) | -202M | -3.9B | -6.1B | (260.8M) | -12.2B | -3.7B | -2.1B | -1.1B | -11.4B | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-497M | -1.3B | -1.2B | -3.8B | -2.3B | -403M | -718M | -238M | -117M | -522M | -2.2B | -2.2B | -1.6B | -2.4B | -77M | -866.8M | -826.3M | -1.1B | 191M | -251.7M | |
-1.6B | -537M | -2.5B | -699M | -248M | -50M | -1.6B | -8.5B | -1.9B | 13.2B | 1.1B | 766M | 1.8B | 4.4B | -4B | 2.1B | 3.7B | -1.2B | -544.5M | 5.7B | |
-4.1B | -3.8B | -3.6B | -3.3B | -3.2B | -2.6B | -2.3B | -2B | -1.8B | -1.5B | -1.4B | -1.3B | -882M | -3.2B | -2.9B | -2.7B | -2.4B | -2.2B | -2B | -1.8B | |
-893M | -1.3B | -1.2B | -3.8B | -2.3B | -403M | -718M | -238M | -827M | -522M | -2.2B | -2.2B | -1.6B | -2.4B | -77M | -866.8M | -826.3M | -1.1B | -1.1B | -754.5M | |
-82M | 264M | 167M | 167M | 255M | 234M | 298M | 271M | -1B | 53M | 297M | 29M | -6B | 1.3B | -96K | 328.4M | 508.7M | 1B | 0.0 | 0.0 | |
-6.3B | -5.4B | -7.1B | -7.6B | -5.5B | -2.8B | -4.3B | -10.4B | -5.3B | 11.1B | -2.2B | -2.7B | -6.7B | 716.1M | -6B | -1.1B | 1B | -3.5B | -2.3B | 3.6B | |
CASH FLOW SUMMARY | ||||||||||||||||||||
71M | -96M | -23M | -122M | -70M | 71M | -16M | -116M | 116M | -483M | -198M | -143M | -26M | 40.1M | -43M | -620.9M | 118.8M | -115.2M | 200.3M | 74M | |
906M | 720M | -3B | 83M | 3B | 3B | 16M | -5.6B | -9.2B | 13.6B | 938M | 588M | -7.3B | 4B | 3.2B | -5.2B | 4.7B | 1.7B | 1.9B | -2.4B | |
7.6B | 6.9B | 9.9B | 9.8B | 6.8B | 3.9B | 3.8B | 9.4B | 18.6B | 5B | 4.1B | 3.5B | 10.8B | 6.8B | 3.6B | 8.8B | 4.1B | 2.5B | 521.2M | 2.9B | |
8.5B | 7.6B | 6.9B | 9.9B | 9.8B | 6.8B | 3.9B | 3.8B | 9.4B | 18.6B | 5B | 4.1B | 3.5B | 10.8B | 6.8B | 3.6B | 8.8B | 4.1B | 2.5B | 521.2M | |
7.4B | 6.4B | 5.1B | 7.8B | 8.6B | 5.7B | 4.5B | 4.9B | 4.4B | 2.1B | 1.9B | 2.6B | 2.2B | 7.5B | 7.5B | 7.7B | 6.2B | 6.1B | 3.5B | 4B |
ABT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 13, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 20, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 20, 2026 | 2026 |
Continue your ABT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.